without any predisposing factor;4 but there is some evidence that Cl difficile may be infectious.i8
There are five reports913 concerning the identification of Cl difficile or its toxin in stools of patients with inflammatory bowel disease: three reports conclude that Cl difficile is found frequently in such patients, especially when there is active inflammation.911
In the present study, stool samples from patients with inflammatory bowel disease have been compared with samples from two groups of control patients. The presence of Cl difficile or its toxin in a patient's stool has been correlated with recent exposure to antibiotics or sulphasalazine, activity of inflammatory bowel disease, and hospital admission. Received for publication 11 October 1982 diagnosis of inflammatory bowel disease was based upon accepted clinical, radiological, and histological criteria.
Whenever a patient was seen as an outpatient, or approximately every week on the ward, a record was made of frequency of bowel actions, the patient's well-being (better, same, worse), the duration of clinical relapse, the presence of blood or mucus in the stool, and the drug therapy (including antibiotic use) during the preceding month. Physical examination included sigmoidoscopy. On the basis of this information, the physician assessed whether the patient's inflammatory bowel disease was in remission or relapse, and then treated the patient appropriately using a conventional combination of steroids, sulphasalazine, and occasionally azathioprine. No Table 1 shows that Cl difficile and/or its toxin were found in 13.2% of stool samples from patients with Crohn's disease, in 13.7% of samples from patients with ulcerative colitis, and in 11.7% of samples from the inpatient controls with diarrhoea. As either culture of Cl difficile or detection of its toxin signifies the presence of the organism in a stool sample, the detection of either marker identified a stool sample as 'Cl difficile positive'. Only one sample from the healthy outpatient controls was positive for Cl difficile (1.3%). .In all three (Crohn's disease, ulcerative colitis, and diarrhoea) groups, positive samples were significantly more frequent than in the healthy outpatient controls (p<0.01). Table 2 shows that the incidence of Cl difficile 
Discussion
Cl difficile is found frequently in the stools of patients with inflammatory bowel disease, without exposure to broad spectrum antibiotics. In the present study 13.4% of stools of patients with inflammatory bowel disease were Cl difficile positive, a result very similar to the 11-9% positive stools from one of this study's control groups (hospital inpatients with diarrhoea) and a study of diarrhoea after antibiotic treatment.t6 The main difference between the two groups in this study was that whereas 66% of the diarrhoea control stools had been exposed recently to antibiotics, only 11% of the samples from the inflammatory bowel disease had been so exposed (p<O0O1). Sixty-seven per cent of the inflammatory bowel disease stools, however, had been exposed to sulphasalazine,, which is deconjugated in the colon, releasing free sulphapyridine in the stools.17
The patients with inflammatory bowel disease with a history of recent antibiotic exposure had a significantly higher incidence of Cl difficile in their stools than those taking only sulphasalazine (31% against 13%, respectively, p<OO1). Stools from patients with inflammatory bowel disease taking neither antibiotics nor sulphasalazine, however, had an even lower incidence of Cl difficile (5.5%). This incidence of positive stools was not significantly different from the 1.3% found in the stools of the other control (outpatient) group, who had a normal bowel habit and no recent exposure to antibiotics.
Although it is suggested that the use of antibiotics facilitates the overgrowth of Cl difficile in the stool,t8 the effects of sulphasalazine on the faecal flora are less certain. Early studies were contradictory, suesting both a rise and a fall of anaerobes,t 0 but a recent study reported no change in the anaerobic flora. 23 it is possible that stool analysis only detects a certain degree of faecal overgrowth with the organism. Indeed, in terms of the pathogenesis of colonic damage, these toxin assays are irrelevant, as the cytotoxin measured in this and most other studies is probably not the toxin that induces colitis. 24 The combination of inexact clinical assessment of disease activity25 and imprecise detection of either Cl difficile or its non-pathogenic toxin, may have obscured any correlation between the two events, especially in outpatients with inflammatory bowel disease.
It is also possible that Cl difficile has no pathogenic role; its proliferation could be facilitated by either a damaged colonic mucosa or by liquid colonic contents during diarrhoea.
Symptomatic improvement of inflammatory bowel disease after uncontrolled vancomycin treatment has been cited as further evidence that Cl difficile may have a pathogenic role in inflammatory bowel disease.9 When the results of the present study were analysed at the end of the year, it was clear that two patients (one with ulcerative colitis and the other with Crohn's colitis) had persistently positive stool samples for Cl difficile. Both patients were ill with continuing colitis despite conventional treatment. They were treated with vancomycin 250 mg qds for 10 days. Cl difficile and its toxin were eradicated from their stools, but the patients' symptoms did not improve dramatically.
The results of the present study show that Cl difficile is found with an increased frequency in the stools of patients with inflammatory bowel disease, suggesting that it may be a cause of illness in some of these patients. Cl difficile was found in the stools of 28% of these patients on one or more occasions during the year. As the laboratory assessment of Cl difficile or its pathogenic toxin may be imprecise, it is possible that its role in inflammatory bowel disease may even have been underestimated by this study. Eradication of colonic Cl difficile may induce remission of colitis. This hypothesis could be tested by a placebo-controlled trial of oral vancomycin in patients with acute colitis in whom conventional laboratory assessment for Cl difficile is negative; a preliminary report of such a study suggests that vancomycin may be of benefit. 26 Clostridia species are important veterinary pathogens, but are controlled by successful innoculation programmes.24 Similar immunisation in man proects against necrotising enterocolitis.28
Human immunisation using Cl difficile toxoid is feasible and would be a practical proposition in a high risk population: patients with inflammatory bowel disease may fulfil this role. 
